Table 1.
Clinical and demographic characteristics of MS patients.
| MS patients (n = 50) | |
|---|---|
| Females n (%) | 37 (74) |
| Males, n (%) | 13 (26 ) |
| Education level, mean years ± SD | 12 ± 2 |
| Professional activity, n (%) | 23 (46) |
| MS form, n (%) | |
| RR | 35 (70) |
| PP | 10 (20) |
| SP | 5 (10) |
| Disease duration, mean years, ± SD | 13 ± 8 |
| EDSS score, median (IQR) (25–75) | 3.0 (2.0–5.0) |
| MS treatments, n (%) | |
| No treatment | 16 (32) |
| Injectable immunomodulators | 15 (30) |
| Natalizumab | 12 (24) |
| Other immunosuppressants | 7 (14) |
| Concomitant treatments, n (%) | |
| Benzodiazepine | 11 (22) |
| Antidepressant | 12 (24) |
| Hypnotic | 1 (2) |
| Antiepileptic | 11 (22) |
| BDI-II score, median (IQR) (25–75) | 14.5 (10–26) |
| Depressive state, n (%) | |
| Minimal | 9 (18) |
| Slight | 20 (40) |
| Moderate | 10 (20) |
| High | 11 (22) |
BDI-II: Beck Depression Inventory; EDSS: Expanded Disability Status Scale; IQR: interquartile range; n: number of patients; MS: multiple sclerosis; RR: relapsing remitting; PP: primary progressive; SD: standard deviation; SP: secondary progressive.